Cite
MLA Citation
Erik J. van Helden et al.. “RAS and BRAF mutations in cell‐free DNA are predictive for outcome of cetuximab monotherapy in patients with tissue‐tested RAS wild‐type advanced colorectal cancer.” Molecular oncology, vol. 13, no. 11, 2019, pp. 2361–2374. http://access.bl.uk/ark:/81055/vdc_100093292048.0x000021